The U.K. National Institute for Health and Clinical Excellence said Bristol-Myers Squibb's Orencia, or abatacept, is not cost-effective for National Health Service use as second-line treatment for adults with moderate to severe rheumatoid arthritis who did not respond to standard nonbiologic medicines. The agency said it already endorsed coverage of several other RA drugs.

Related Summaries